# Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

> **NCT05013554** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 44 (actual)

## Conditions studied

- Neoplasm Malignant
- Breast Cancer
- Lung Neoplasm Malignant
- Gastric Cancer
- Neoplasm

## Interventions

- **DRUG:** SAR443216 IV
- **DRUG:** SAR443216 SC

## Key facts

- **NCT ID:** NCT05013554
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-16
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013554, "Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05013554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*